Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 – (ACN Newswire) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. Apollomics licensed the Greater China rights for uproleselan from GlycoMimetics. “As our first Phase 3 clinical trial, dosing of the first patient wit…

Read More